Jill Feldman

Profile picture of Jill Feldman

Steering Committee Member
Survivorship Task Group Chair

Patient Advocate EGFR Resisters

Jill Feldman is a lung cancer patient and advocate. When Jill was 13 years old, she lost her dad and two grandparents to lung cancer and then her mom and close aunt died of lung cancer when she was in her 20’s. She became a volunteer, an advocate and past president of LUNGevity Foundation before the unthinkable happened. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR positive lung cancer.

Jill continues to be involved with LUNGevity. She is also Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.

Jill has presented patient perspectives at conferences, including the World Conference on Lung Cancer hosted by IASLC and the virtual ASCO Education Program. She is a co-author of the ASTRO Guidelines for SBRT in early stage lung cancer that was published in an ASCO special article in the Journal of Clinical Oncology. 2017, Jill co-founded the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFRm lung cancer. Jill also continues to share her story in the media and at various events and participates in countless advocacy opportunities to shine a light on lung cancer and end the stigma associated with it.